Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL SA versus KAINAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL SA versus KAINAIR.
CHOLEDYL SA vs KAINAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
25 mg subcutaneously three times daily.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Category C
Category C
Bronchodilator
Bronchodilator